Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue ... followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the parent company of Medical Device ...